Central retinal artery occlusion (CRAO) is a form of acute ischemic stroke.1 Despite >150 years of research, there are no effective evidence-based forms of therapy for this condition. Fewer than 20% of affected patients regain functional visual acuity in the affected eye.2,3 Analogous to cerebral ischemic stroke, CRAO is associated with a risk of recurrent vascular events.4–8 The efficacy of widely used treatment strategies for this condition has not been tested in randomized placebo-controlled clinical trials. In this scientific statement, we discuss the management of CRAO with particular reference to acute therapy and cardiovascular secondary prevention strategies.
top of page
bottom of page